PROGRAM CHAIR
Paradi Mirmirani, MD
Department of Dermatology
Kaiser Permanente
Interim Medical Director, Clinical Trials Program
Regional Director, Hair Disorders
Physician Lead for Dermatology Research, Education and Academics
San Francisco, California
FACULTY PRESENTER
Jennifer Fu, MD
UCSF Hair Disorders Clinic
Department of Dermatology
San Francisco, California
PROGRAM OVERVIEW
This activity addresses the evolving educational needs of dermatologists, pediatric dermatologists, nurse practitioners, and physician assistants who care for adult and pediatric patients with alopecia areata (AA). It focuses on enhancing clinicians’ understanding of the substantial disease burden associated with AA, including its psychosocial impact and the broader clinical factors that influence patient outcomes. Through evidence-based content and practical guidance, the program strengthens clinicians’ ability to incorporate comprehensive disease severity assessment tools that account for patient quality of life and non–scalp hair involvement, enabling more accurate and individualized evaluations. In addition, this activity supports clinicians in critically appraising clinical data for current and emerging Janus kinase (JAK) inhibitors in both pediatric and adult populations, with the goal of optimizing treatment selection and appropriately intensifying therapy based on disease severity and patient needs.
TARGET AUDIENCE
This activity is designed to meet the education needs of dermatologists, pediatric dermatologists, nurse practitioners, and physician assistants who treat adult and pediatric patients with alopecia areata (AA)
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the psychosocial impact and other factors that contribute to the high disease burden of alopecia areata.
- Utilize disease severity assessment tools that consider patient quality of life and non–scalp hair loss to more accurately assess the severity of alopecia areata.
- Assess the clinical data for current and emerging JAK inhibitors for pediatric and adult patients with AA to appropriately intensify treatment.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 2.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 2.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Jennifer Fu, MD | Consulting fees: Eli Lilly, Pfizer, Sun Pharmaceuticals, Veradermics Speaker Bureau: LearnSkin Contracted research: Priovant |
| Paradi Mirmirani, MD | Consulting fees: Lilly, Pfizer, Sun Pharma, Veradermics Contracted research: Lilly, Pfizer, Sun Pharma |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Nicolas Applyrs, DO, has nothing to disclose
- Sarah Milano, RN, MSN, has nothing to disclose
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Melissa Johnson, Program Director for Med Learning Group, has nothing to disclose.
- Millena Papastavrou, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, M.M. Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
RELEASED DATE: June 30, 2026
EXPIRATION DATE: June 30, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
